Reviewer's report
Title:Immunophenotype classification and therapeutic outcomes of Chinese
primary gastrointestinal diffuse large B-cell lymphoma
Version: 2Date:22 May 2012
Reviewer: Bogna Ziarkiewicz-Wroblewska
Reviewer's report:
Minor Essential Revisions
1. The pages of manuscript are not numbered, which makes the revision difficult.
So I gave the numbers myself....
a) page 5: the number of reference is neededin the 6th line after the name
"Dawson"
b) I found some spelling mistakes; for example:
- two dots - page 5
- DLBLC - page 9
- confirm(ed) diagnosis - page 3
- ; T(t)he third type - page 10
Discretionary Revisions
1. The current WHO classification of tumours of haematopoietic and lymphoid
tissues divides DLBCL into 3 immunohistochemical groups: GCB, non-GCB, and
CD5 positive DLBCL. It might be interesting to examine CD5 expression, and its
relation to the clinical parameters assessed by authors.
2. Three months of follow-up seems to be very short in monitoring the results of
DLBCL treatment. I think 6 months is the minimum; maybe it would be
reasonable to exclude the cases observed less than 6 months from the analysis.
3. Five patients treated with R-CHOP in GCB group are not sufficient for
statistical analysis, and to draw the conclusion.
4. Tables 1 and 2 can be joined.
5. Fig. 1 is very clear and facilitates immunohistochemical results interpretation -
but I am not sure, if it is really necessary.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Immunophenotype classification and therapeutic outcomes of Chinese
primary gastrointestinal diffuse large B-cell lymphoma
Version: 2Date:22 May 2012
Reviewer: Bogna Ziarkiewicz-Wroblewska
Reviewer's report:
Minor Essential Revisions
1. The pages of manuscript are not numbered, which makes the revision difficult.
So I gave the numbers myself....
a) page 5: the number of reference is neededin the 6th line after the name
"Dawson"
b) I found some spelling mistakes; for example:
- two dots - page 5
- DLBLC - page 9
- confirm(ed) diagnosis - page 3
- ; T(t)he third type - page 10
Discretionary Revisions
1. The current WHO classification of tumours of haematopoietic and lymphoid
tissues divides DLBCL into 3 immunohistochemical groups: GCB, non-GCB, and
CD5 positive DLBCL. It might be interesting to examine CD5 expression, and its
relation to the clinical parameters assessed by authors.
2. Three months of follow-up seems to be very short in monitoring the results of
DLBCL treatment. I think 6 months is the minimum; maybe it would be
reasonable to exclude the cases observed less than 6 months from the analysis.
3. Five patients treated with R-CHOP in GCB group are not sufficient for
statistical analysis, and to draw the conclusion.
4. Tables 1 and 2 can be joined.
5. Fig. 1 is very clear and facilitates immunohistochemical results interpretation -
but I am not sure, if it is really necessary.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Immunophenotype classification and therapeutic outcomes of Chinese
primary gastrointestinal diffuse large B-cell lymphoma
Version: 2Date:22 May 2012
Reviewer: Bogna Ziarkiewicz-Wroblewska
Reviewer's report:
Minor Essential Revisions
1. The pages of manuscript are not numbered, which makes the revision difficult.
So I gave the numbers myself....
a) page 5: the number of reference is neededin the 6th line after the name
"Dawson"
b) I found some spelling mistakes; for example:
- two dots - page 5
- DLBLC - page 9
- confirm(ed) diagnosis - page 3
- ; T(t)he third type - page 10
Discretionary Revisions
1. The current WHO classification of tumours of haematopoietic and lymphoid
tissues divides DLBCL into 3 immunohistochemical groups: GCB, non-GCB, and
CD5 positive DLBCL. It might be interesting to examine CD5 expression, and its
relation to the clinical parameters assessed by authors.
2. Three months of follow-up seems to be very short in monitoring the results of
DLBCL treatment. I think 6 months is the minimum; maybe it would be
reasonable to exclude the cases observed less than 6 months from the analysis.
3. Five patients treated with R-CHOP in GCB group are not sufficient for
statistical analysis, and to draw the conclusion.
4. Tables 1 and 2 can be joined.
5. Fig. 1 is very clear and facilitates immunohistochemical results interpretation -
but I am not sure, if it is really necessary.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: Yes, but I do not feel adequately qualified to assess the
statistics.
Declaration of competing interests:
I declare that I have no competing interests.
assistant